NASDAQ:KALA - Kala Pharmaceuticals Stock Price, Price Target & More

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Kala Pharmaceuticals (NASDAQ:KALA) issued its quarterly earnings results on Thursday, May, 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.00. View Kala Pharmaceuticals' Earnings History.

5 brokerages have issued twelve-month target prices for Kala Pharmaceuticals' stock. Their predictions range from $19.00 to $46.00. On average, they anticipate Kala Pharmaceuticals' stock price to reach $35.80 in the next year. View Analyst Ratings for Kala Pharmaceuticals.

Some companies that are related to Kala Pharmaceuticals include Zogenix (ZGNX), Innoviva (INVA), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN), Endo International (ENDP), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Myovant Sciences (MYOV), Impax Laboratories (IPXL), Biohaven Pharmaceutical (BHVN), Amneal Pharmaceuticals (AMRX), Radius Health (RDUS), TherapeuticsMD (TXMD), Epizyme (EPZM) and Theravance Biopharma (TBPH).

(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

News headlines about KALA stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kala Pharmaceuticals earned a daily sentiment score of 0.11 on Accern's scale. They also assigned headlines about the company an impact score of 45.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

Kala Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.10%), Millennium Management LLC (4.06%), Wells Fargo & Company MN (1.48%), JPMorgan Chase & Co. (0.82%), Asymmetry Capital Management L.P. (0.55%) and Northern Trust Corp (0.54%). Company insiders that own Kala Pharmaceuticals stock include Associates LLC Cdk, Longitude Capital Partners Ii,, Orbimed Advisors Llc and Rajeev M Shah. View Institutional Ownership Trends for Kala Pharmaceuticals.

KALA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc. and JPMorgan Chase & Co.. View Insider Buying and Selling for Kala Pharmaceuticals.

KALA stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Asymmetry Capital Management L.P., Wells Fargo & Company MN, Northern Trust Corp, Sofinnova Ventures Inc, Schwab Charles Investment Management Inc. and Tiverton Asset Management LLC. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Associates LLC Cdk, Longitude Capital Partners Ii,, Orbimed Advisors Llc and Rajeev M Shah. View Insider Buying and Selling for Kala Pharmaceuticals.

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of KALA stock can currently be purchased for approximately $15.40.

Kala Pharmaceuticals has a market capitalization of $371.38 million and generates $40,000.00 in revenue each year. The company earns $-42,210,000.00 in net income (profit) each year or ($5.84) on an earnings per share basis. Kala Pharmaceuticals employs 37 workers across the globe.

Kala Pharmaceuticals' mailing address is 100 BEAVER STREET SUITE 201, WALTHAM MA, 02453. The company can be reached via phone at 781-996-5252 or via email at [email protected]